Neurology
Conference Coverage
Signs point to growing abuse of gabapentinoids in the U.S.
LAS VEGAS – Several states have made gabapentin a Schedule V controlled substance while others have mandatory reporting of its dispensing and...
FDA/CDC
FDA review supports Nuplazid’s safety
Conference Coverage
Mild cognitive impairment risk slashed by 19% in SPRINT MIND
Clinicians are calling blood pressure drugs the first disease-modifying therapy for MCI.
For Residents
Intellectual disability impedes decision-making in organ transplantation
Latest News
Confirmed: Growth in overdose deaths is exponential
Opioid epidemic appears to be “the most recent manifestation of a more fundamental, longer-term process.”
Cases That Test Your Skills
Depressed and confused, and dizzy while walking the dog
Mr. M, age 73, feels light-headed and has difficulty following conversations. He has a history of depression, cardiovascular disease, and visual...
From the Journals
Burden of dementia will shift more to minorities by 2060
More culturally competent and appropriate interventions may be required.
Pearls
Use psychoeducational family therapy to help families cope with autism
News from the FDA/CDC
FDA issues new REMS for immediate-release opioids
For the first time, training will be made available to health care providers, nurses, and pharmacists involved in pain management.
From the Editor
10 Recent paradigm shifts in the neurobiology and treatment of depression
The serendipity of half a century ago that hatched hoary theories of the etiology of psychopathology is fading rapidly. Transformative models are...
From the Journals
Tau PET tracer distinguishes Alzheimer’s from other disorders
It was less accurate for distinguishing mild cognitive impairment caused by Alzheimer’s versus non-Alzheimer’s neurodegenerative conditions.